<DOC>
	<DOCNO>NCT01651312</DOCNO>
	<brief_summary>The study aim assess route extent metabolism excretion YM178 single dose 14C-radiolabeled YM178 administer drinking solution healthy male volunteer .</brief_summary>
	<brief_title>A Study Assess Systemic Pharmacokinetics , Metabolism Excretion Routes YM178 Man , After Administration Radio-labeled YM178</brief_title>
	<detailed_description>Four subject study one group . Each subject stay clinic 6 day , receive single oral dose 14C-labeled YM178 . Blood , plasma , urine , feces expire air collect 96h dosing . If 14C-radioactivity quick count show radioactivity urine feces acceptable limit ( ie . &gt; 50 dpm/ml urine ; &gt; 75 dpm 400 mg feces ) day 5 , subject request stay clinic level decrease . If , 3 day , radioactivity still &gt; 50 dpm/ml urine and/or &gt; 75 dpm 400 mg feces , urine and/or feces collect home , amount radioactivity decrease .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body weight 60 100 kg , BMI ≤30 kg/m2 Known suspect hypersensitivity βadrenergic receptor agonists constituent formulation use Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug Any clinically significant history upper gastrointestinal symptom ( nausea , vomit , abdominal discomfort upset , heartburn ) 4 week prior admission Research Unit Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic Abnormal pulse rate measurement ( &lt; 40 &gt; 90 bpm ) take manual counting prestudy visit subject rest supine position 5 min Abnormal blood pressure measurement take prestudy visit subject rest supine position 5 min follow : Systolic blood pressure &lt; 95 &gt; 160 mmHg ; Diastolic blood pressure &lt; 40 &gt; 95 mmHg . Positive orthostatic test screening i.e . symptom dizziness , lightheadedness etc . and/or fall ≥ 20 mmHg systolic blood pressure 2 min standing ( precede 5 min . supine rest ) and/or increase pulse rate ≥ 20 bpm Regular use prescribe OTC ( counter ) drug except paracetamol 3 g/day , 4 week prior admission Research Unit OR use drug 2 week prior admission Research Unit History drug abuse time , OR use drug abuse within 3 month prior admission Research Unit History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Research Unit History drink 21 unit alcohol per week ( 1 unit = 270 cc beer 40 cc spirit 1 glass wine ) within 3 month prior admission Research Unit Donation blood blood product within 3 month prior admission Research Unit Positive serology test HBsAg , HAV IgM , antiHCV antiHIV 1+2 . Participation clinical study within 3 month , participation 3 clinical study within 12 month , prior expect date enrolment study Subjects receive YM178 previously Exposure radiation diagnostic reason ( except dental Xrays plain Xrays thorax bony skeleton ( exclude spinal column ) ) , work participation clinical trial previous year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Radioactivity</keyword>
	<keyword>Excretion rate</keyword>
	<keyword>Human subject</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>YM178</keyword>
	<keyword>Radio-labeled</keyword>
	<keyword>Phase 1</keyword>
</DOC>